Search

everythinglearnresearchcommunity

for

Search:↓

Certain immune cells in the skin release a protein that stops hair growth by keeping hair stem cells inactive.

Keratin 6A increases skin inflammation, suggesting it could be a target for treating certain skin diseases.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

CMX from Centipeda minima can significantly improve hair growth in mild to moderate balding.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

JAK inhibitors show promise for treating various skin diseases.

Chinese patients with alopecia areata value JAK inhibitors but worry about side effects and relapse, highlighting the need for education and support.

JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.

MJ04, a new compound, effectively promotes hair growth and is a potential topical treatment for hair loss.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

JAK inhibitors do not improve hair regrowth in androgenic alopecia but may prevent further hair loss.

JAK inhibitors show promise for treating alopecia areata but have serious side effects.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.

TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.

Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

JAK inhibitors can enter the skin through hair follicles using a unique pathway.

NSC167409 can effectively inhibit the virus causing hand, foot, and mouth disease.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

IL-15 promotes hair growth and protects hair follicles.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Ruxolitinib can cause a delayed skin reaction on the nose.

Chemotherapy-induced hair loss may be linked to immune system changes, and certain treatments could help but need careful use.

Baricitinib effectively improved skin and hair conditions in a patient with alopecia areata and atopic dermatitis.

Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.